论文部分内容阅读
采用绿脓杆菌 MSHA菌毛株菌苗 (PA - MSHA菌苗 )治疗了 40例使用抗生素无效的 RU TI,取得了满意的疗效 ,有效率 95 % (38/ 40 ) ,治愈率 92 .5 % (37/ 40 )。对其中 18例进行了治疗前后血清抗MSHA菌毛株抗体效价和外周血 T淋巴细胞亚群测定。疗后患者血清中抗 MSHA菌毛株抗体效价较疗前增高 8～ 6 4倍 ;同时外周血 T淋巴细胞亚群的比例得到了改善 ,CD+ 3 和 CD+ 4 T细胞的百分率显著提高 (P<0 .0 1) ,而 CD+ 8T细胞的百分率则显著下降 (P<0 .0 0 1)。治疗过程未见明显的副作用。研究表明 :PA-MSHA菌苗对反复发作性尿路感染治愈率高 ,安全可靠 ,患者的免疫低下状态得到改善 ,且对多种病原菌(包括革兰阴性杆菌及其 L 型、金黄色葡萄球菌及其 L 型 )所致的 RU TI效果都很好。
Forty cases of RU TI with antibiotic failure were treated with Pseudomonas aeruginosa MSHA strain (PA - MSHA vaccine), with satisfactory curative effect, the effective rate was 95% (38/40) and the cure rate was 92.5% (37/40). Serum anti-MSHA antibody titer and peripheral blood T-lymphocyte subsets were measured before and after 18 cases were treated. After treatment, the anti-MSHA antibody titer in serum of patients was increased by 8 ~ 64 times compared with that before treatment. At the same time, the proportion of T lymphocyte subsets in peripheral blood was improved, while the percentage of CD + 3 and CD + 4 T cells was significantly increased (P <0.01), while the percentage of CD + 8T cells decreased significantly (P <0.01). No obvious side effects of treatment. The results showed that: PA-MSHA vaccine has high cure rate, safe and reliable for recurrent urinary tract infection, and the immunocompromised condition of the patients is improved. It also has the effect on a variety of pathogens (including Gram-negative bacilli and L type, Staphylococcus aureus And its L-type) caused by the RU TI are good.